The Fight for Sinovac

At the height of the pandemic, Chinese vaccine maker Sinovac was a hero and one of the country’s most promising companies. But its success masked a protracted dispute between rival investors and management for control of the cash-rich company. The Wire China investigates what went wrong.

Stay ahead of U.S. export rules. Comply with the new 50% ‘Affiliates Rule.’

  • Full coverage of Entity, MEU, and SDN lists
  • Automatic ownership + control risk flags
  • Enhanced due diligence on Chinese companies
Register Now

Libel Lawfare

In recent years, several large Chinese companies have filed defamation suits against small organizations or individual researchers, leading to a strange reality: Even as the general rhetoric against China has become more hawkish, many in...

China Plans, America Reacts

Trumponomics, lacking an overarching strategy and largely based on the whims of one man, is nothing like China’s comprehensive “all-of-government” approach.

Taiwan’s Achilles’ Heel

Taiwan is almost entirely dependent on imported fossil fuels for its power supply — a critical weakness in the event of a Chinese blockade. But the very democratic forces on the island that China would...